• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results

    5/2/22 8:00:00 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LIFE alert in real time by email

    SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report first quarter 2022 financial results and provide a corporate update after the market close on Monday, May 9, 2022. Management will host a conference call and webcast to review the results and provide an operational update.

    Conference Call and Webcast Details:

    Monday, May 9th @ 5:00 p.m. EDT / 2:00 p.m. PDT

    Domestic: 844-358-9116

    International: 209-905-5951

    Conference ID: 9273437

    Webcast: http://investors.atyrpharma.com/events-and-webcasts

    About aTyr

    aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr's research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr's primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com.

    Contact:

    Ashlee Dunston

    Director, Investor Relations and Corporate Communications

    [email protected]



    Primary Logo

    Get the next $LIFE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIFE

    DatePrice TargetRatingAnalyst
    7/5/2023Outperform → Perform
    Oppenheimer
    11/11/2021$18.00 → $11.00Buy
    HC Wainwright & Co.
    11/11/2021$18.00 → $11.00Action List Buy
    HC Wainwright & Co.
    10/12/2021$22.00Outperform
    RBC Capital
    9/21/2021$19.00Overweight
    Piper Sandler
    9/14/2021$20.00 → $21.00Buy
    Roth Capital
    9/14/2021$14.00 → $20.00Outperform
    Oppenheimer
    9/13/2021$13.00 → $18.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LIFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Denyes Nancy bought $9,276 worth of shares (5,000 units at $1.86), increasing direct ownership by 29% to 22,267 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/6/24 8:26:55 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coughlin Timothy bought $87,500 worth of shares (50,000 units at $1.75) (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 4:21:12 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Broadfoot Jill Marie bought $8,950 worth of shares (5,000 units at $1.79), increasing direct ownership by 22% to 27,960 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 8:38:39 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"

      SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from "LIFE" to "ATYR." Effective at the market open on June 5, 2024, the Company's common stock will trade on the Nasdaq Capital Market under the new symbol "ATYR." "As we advance our lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis and prepare for potential commercialization, the "ATYR" ticker symbol is a strong reflec

      6/3/24 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 9,400 shares of aTyr's common stock, each with an exercise price of $1.86 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on May 22, 2024, the effective date of the grants. These stock awards were granted as an inducement material

      5/24/24 4:00:00 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

      SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2024 International Conference, which is scheduled to take place May 17 – 22 in San Diego, CA. "These findings further demonstrate the unique way in which efzofitimod is modulating myeloid cells to confer the anti-inflammatory benefits we have seen in patients with pulmonary sarcoidosis, a major form o

      5/15/24 7:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LIFE
    Financials

    Live finance-specific insights

    See more

    $LIFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Denyes Nancy bought $9,276 worth of shares (5,000 units at $1.86), increasing direct ownership by 29% to 22,267 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/6/24 8:26:55 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coughlin Timothy bought $87,500 worth of shares (50,000 units at $1.75) (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 4:21:12 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Broadfoot Jill Marie bought $8,950 worth of shares (5,000 units at $1.79), increasing direct ownership by 22% to 27,960 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 8:38:39 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

      Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

      3/14/24 4:00:00 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

      SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7

      2/28/24 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

      SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 9, 2023Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051

      3/2/23 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

      SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

      2/14/24 1:43:55 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

      SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

      2/13/24 4:30:17 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

      SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

      2/9/24 8:35:54 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Leadership Updates

    Live Leadership Updates

    See more
    • aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

      SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

      1/18/24 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

      SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human Resources. Ms. Campbell will serve as a member of the company's executive leadership team and oversee all aspects of human resources strategies and functions, including organizational development, talent management and talent acquisition initiatives. "We are delighted to welcome Danielle to aTyr at a pivotal time in the company's journey as we expand our team to support our next phase of growth," said Sanjay S.

      12/24/21 8:02:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

      NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ

      11/2/21 9:00:00 AM ET
      $AMGN
      $APVO
      $BCTX
      $BMY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $LIFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • aTyr Pharma downgraded by Oppenheimer

      Oppenheimer downgraded aTyr Pharma from Outperform to Perform

      7/5/23 7:41:57 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Buy and set a new price target of $11.00 from $18.00 previously

      11/11/21 6:10:41 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Action List Buy and set a new price target of $11.00 from $18.00 previously

      11/11/21 6:10:41 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    SEC Filings

    See more
    • aTyr Pharma Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Other Events, Financial Statements and Exhibits

      8-K - aTYR PHARMA INC (0001339970) (Filer)

      5/29/24 4:03:07 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by aTyr Pharma Inc.

      10-Q - aTYR PHARMA INC (0001339970) (Filer)

      5/2/24 4:07:23 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - aTYR PHARMA INC (0001339970) (Filer)

      5/2/24 4:04:01 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care